# CENTER FOR DRUG EVALUATION AND RESEARCH 75-273

**APPLICATION NUMBER:** 

**CHEMISTRY REVIEW(S)** 

CHEMISTRY REVIEW NO. 3 1. 2. ANDA # 75-273 3. NAME AND ADDRESS OF APPLICANT Teva Pharmaceuticals USA 1510 Delp Drive Kulpsville, PA 19443 4. LEGAL BASIS FOR SUBMISSION The firm certifies that to the best of their knowledge and in their opinion there is one patent claims the listed drug. U.S. Patent # 4335125 which expires June 15, 1999 The applicant will not engage in the commercial manufacture, use, or sale of the drug product until the expiration of U.S. Patent #4335125. The firm certifies that to the best of their knowledge and in their opinion, there exists no listed exclusivities for the referenced drug product. 5. SUPPLEMENT(s) 6. PROPRIETARY NAME N/A N/A 7. NONPROPRIETARY NAME 8. SUPPLEMENT(s) PROVIDE(s) FOR: Ketoconazole N/A 9. <u>AMENDMENTS AND OTHER DATES:</u> Amendment 3/23/99 (tentative to final) 10. PHARMACOLOGICAL CATEGORY Treatment of systemic fungal infections

11.

12.

13.

Rx or OTC

DOSAGE FORM

Tablets

RELATED IND/NDA/DMF(s)

14.

**POTENCY** 

200 mg

Rx

### 15. CHEMICAL NAME AND STRUCTURE

Ketoconazole. Piperazine, 1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazole-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-, cis-.  $C_{26}H_{28}Cl_2N_4O_4$ . 531.44. 65277-42-1. Antifungal. USP 23, page 864.

### 17. COMMENTS

Previously (10/29/98) tentatively approved.

Minor modifications are acceptable.

DMF and EER are acceptable.

## 18. CONCLUSIONS AND RECOMMENDATIONS

The application is approvable.

# 19. REVIEWER:

DATE COMPLETED:

Nashed E. Nashed, Ph.D.

5/25/99

Supervisor: Paul Schwartz, Ph.D.

CC:

**Endorsements:** 

HFD-627/NNashed/5/25/99

HFD-627/PSchwartz/5/28/99

\\CDV008\WP51F99\FIRMSNZ\TEVA\LTRS&REV\75273.3.DOC

F/t by: gp/5/28/99

Contain Trade Secret,

Commercial/Confidential

Information and are not
releasable.

chem Rev 3 5/25/99